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Risk, Risk Factors, and Surveillance of Subsequent Malignant
Neoplasms in Survivors of Childhood Cancer: A Review
Lucie M. Turcotte, Joseph P. Neglia, Raoul C. Reulen, Cecile M. Ronckers, Flora E. van Leeuwen, Lindsay M.
Morton, David C. Hodgson, Yutaka Yasui, Kevin C. Oefﬁnger, and Tara O. Henderson
A B S T R A C T
Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity
and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, sur-
veillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk
compared with the general population, with a greater than twofold increased solid tumor risk
extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after
radiotherapy, with the highest risks for tumors occurring in or near the treatment ﬁeld (eg, greater
than ﬁvefold increased risk for breast, brain, thyroid, skin, bone, and soft tissue malignancies).
Alkylating and anthracycline chemotherapies increase the risk for development of several solid
malignancies in addition to acute leukemia/myelodysplasia, and these risks may be modiﬁed by
other patient characteristics, such as age at exposure and, potentially, inherited genetic suscep-
tibility. Strategies for identifying survivors at risk and initiating long-term surveillance have improved
and interventions are underway to improve knowledge about late-treatment effects among sur-
vivors and caregivers. Better understanding of treatment-related risk factors and genetic suscep-
tibility holds promise for reﬁning surveillance strategies and, ultimately, upfront cancer therapies.
J Clin Oncol 36. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Survival after childhood cancer now exceeds 80%
throughout the United States and much of
Europe.1,2With this improvement in survival over
the last ﬁve decades, there has been increased
recognition of late health complications, includ-
ing subsequent malignant neoplasms (SMNs),
among survivors. SMNs, deﬁned as new primary
malignancies after an initial cancer diagnosis, are
the most frequent cause of nonrelapse late
mortality, accounting for nearly half of non-
relapse deaths among 5-year survivors.3 This
review highlights up-to-date evidence on SMN
risk, risk factors, and surveillance efforts.
CUMULATIVE INCIDENCE AND RISK FOR
SUBSEQUENT NEOPLASMS
Multi-institution and population-based cohort
studies, based in Europe and North America,
designed to follow long-term survivors of
childhood cancer, have been instrumental in de-
scribing SMN epidemiology. These cohort con-
sortia have led efforts to characterize late effects
experienced by survivors and have provided
important data that have helped guide current
cancer therapies and guidelines for surveillance of
survivors of childhood cancer.
The largest SMN series have been reported
by the North American Childhood Cancer Sur-
vivor Study (CCSS), the British Childhood
Cancer Survivor Study (BCCSS), a collaborative
effort from the Nordic countries cancer registries,
and the Dutch Childhood Cancer Oncology
Group-Long-Term Effects After Childhood
Cancer (DCOG-LATER) cohort. These groups
have shown that an increased SMN risk persists
with advancing attained age. All four studies re-
ported that beyond age 40 years, the standardized
incidence ratio (SIR) was at least twofold and that
the absolute excess risk (AER) increased with
attained age (Fig 1).7,10-12 Despite consistent SIRs
and AERs across cohorts before age 40 years, the
CCSS and DCOG-LATER studies reported higher
SIRs and AERs than the BCCSS or Nordic
countries for older attained ages. A potential
explanation is that the BCCSS and the Nordic
country cohorts include patients who received
their diagnosis between 1940 and 1969, an era of
low overall survival rates for pediatric cancer.
Most survivors from this era received treatments
with minimal carcinogenic potential, such as
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surgery alone, low-energy radiotherapy, or single-agent chemo-
therapy. Because survivors treated before 1970 make up the ma-
jority of patients with higher attained ages, it is not surprising that
the treatment-related excess risks are lower.4
The ﬁrst analysis of SMN risk from the CCSS reported
a 20-year cumulative incidence of 3.2%, with a sixfold increased
risk compared with the general population (SIR, 6.4; 95%CI, 5.7 to
7.1).5 In a follow-up report, SMN cumulative incidence was re-
ported at 30 years and had increased to 7.9%, whereas the risk for
malignancy remained stable from the previous report (SIR, 6.0;
95% CI, 5.5 to 6.4), with the greatest SIRs observed for cancers of
the bone, CNS, thyroid, head and neck, and breast.6 Survivors
experienced a fourfold increased risk of developing a malignancy
after age 40 years compared with the general population (SIR, 4.4;
95% CI, 3.8 to 5.0), with the greatest risk observed for cancers of the
breast, kidney, thyroid, and soft tissue sarcoma (STS).7 The most
recent comprehensive report of SMNs from the CCSS reported
15-year cumulative SMN incidence by decade of diagnosis and
showed that those whose cancer was diagnosed in the 1990s had
a signiﬁcantly lower incidence of subsequent malignancy compared
with those diagnosed in the 1970s (1.3% v 2.1%; P , .001).8
Within Great Britain, before the development of the BCCSS,
SMN incidence and risk were reported from a retrospective cohort of
16,541 3-year survivors of childhood cancer who were identiﬁed
through the National Register of Childhood Tumors.9 Among
survivors of nonretinoblastoma primary cancers, the 20-year cu-
mulative SMN incidence was 2.8% and survivors experienced
a nearly sixfold increased risk for malignancy compared with the
general population (SIR, 5.8; 95% CI, 5.0 to 6.7). The greatest risk
was observed for cancers of the bone, CNS, endocrine system, and
STS.9 Subsequently, the population-based BCCSS reported on long-
term risks of SMNs in 17,981 5-year survivors whose cancer was
diagnosed when they were between age 0 and 14 years between 1940
and 1991.10 The study identiﬁed a fourfold increased risk for SMNs
compared with the general population (SIR, 3.9; 95% CI, 3.6 to
4.2).10 The BCCSS showed that survivors remain at increased risk for
SMNs beyond age 40 years, with a 2.5-fold increased SIR for ages
40 to 49 years (95%CI, 2.1 to 3.0) and 1.7-fold increased SIR beyond
50 years (95% CI, 1.4 to 2.1). The greatest AER after age 40 years was
for SMNs of the GI (AER, 5.9 per 10,000 person-years) and geni-
tourinary (AER, 6.0 per 10,000 person-years) systems, with these two
sites accounting for 36% of the total AER after age 40 years.10
The combined Nordic cohort, which consists of registry data
from Denmark, Finland, Iceland, Norway, and Sweden, spans the
diagnosis years between 1943 and 2005. This study11 identiﬁed
a threefold increased risk for a SMN compared with the general
population (SIR, 3.3; 95% CI, 3.1 to 3.5) and showed the highest
risk for developing SMNs of the bone, connective tissue, CNS, and
endocrine glands. The risk for a SMN occurring between ages
40 and 70 years was 1.5- to 2.3-fold that of the general population.
Individuals treated in the most recent era of study (1975 to 2005)
experienced higher age-speciﬁc incidence rates compared with
those treated earlier.11
The DCOG-LATER study reported a ﬁvefold increase in SMN
SIR compared with the general population (SIR, 5.2; 95% CI, 4.6 to
5.8) among 6,165 5-year survivors diagnosed between 1963 and
2001, and a 25-year cumulative SMN incidence of 3.9%.12 The SIR
was still signiﬁcantly increased after$ 30 years (SIR, 3.8; 95%CI, 2.8
to 4.9) and the AER substantially increased with increasing follow-up
time. There was no signiﬁcant decrease in cumulative incidence of
SMNs for survivors treated in the 1990s compared with those treated
earlier, in contrast to what was reported by the CCSS.8,12
Collaborative work among multiple European countries is
forthcoming under the umbrella of the Pan-European Network for
Care of Survivors after Childhood and Adolescent Cancer (Pan-
Care). Pooled cohort and case-control studies on the risk of SMNs
among 69,460 5-year survivors across 12 European countries are
underway.13 This large-scale study provides a means for consistent
data collection and reporting across cohorts and overcomes the
limitations in size and available data observed in previous studies.14
RISK FACTORS
Radiotherapy and SMN Development
Radiation dose–related SMN risk has been studied for many
cancers, as summarized in Fig 2.15 Dose-response studies rely on
the radiotherapy target dose (ie, the dose delivered to the tumor
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Fig 1. Standardized incidence ratios and absolute excess risk of subsequent malignant neoplasm by attained age in international cohorts of survivors of childhood
cancer.
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and its surroundings), which is valid for proximal tissues. For more
distant tissues, exposures are estimated using dose-reconstruction
methods, accounting for patient and treatment characteristics (eg,
treatment dose, beam energy, ﬁeld size and conﬁguration).16
CNS tumors occur in excess after cranial radiotherapy, mainly
among survivors of pediatric brain tumors and acute leukemia.10
The CCSS and BCCSS reported dose-response trends for glioma
(excess odds ratio [EOR] per Gy, 0.33 and 0.079, respectively) and
nonmalignant and malignant meningioma (EOR per Gy, 1.06 and
5.1, respectively).17,18 A 39-fold excess risk of salivary gland tumors
was reported by the CCSS, with an estimated excess relative risk per
Gy of 0.36, with most observed cases occurring after leukemia or
lymphoma.19 An international pooled analysis of thyroid cancer in
survivors of childhood cancer showed a dose-response plateau be-
tween 10 and 30 Gy and decreasing risk at higher doses (Fig 3),20
hypothesized to be due to cell killing, with stronger dose-responses
for those who were youngest at the time of exposure.20 Additional
analysis of low-dose radiation exposure showed signiﬁcant dose-
response trends at , 0.2 and , 0.1 Gy (P , .01) persisting . 45
years after exposure.21
Data on lung cancer in cohorts of survivors of childhood
cancer are limited. The Nordic cohort reported eight cases, for
a 3.9-fold increased risk (95% CI, 1.7 to 7.6) in survivors with an
attained age of 40 to 79 years.11 In addition, large studies of
survivors of Hodgkin lymphoma (HL) who were treated as chil-
dren and young adults showed that lung cancer risk was elevated
after chest radiation and that radiation incurred a multiplicative
effect in smokers.22,23
Female breast cancer risk is increased, particularly after chest/
absorbed doses. 10 Gy,24 with an established linear dose-response
relationship (Fig 4).25 There is growing evidence for heightened
radiation sensitivity surrounding menarche,26 with risk persisting
40 to 45 years after radiotherapy,7,22 and reduction of radiation-
related risk among women with premature menopause (Fig 4).25
Cumulative incidence of breast cancer by age 50 years in women
treated with chest irradiation for HL has been estimated at 35%. The
cumulative incidence by age 45 years for other survivors of childhood
cancer treated with chest irradiation was 15%, presumably lower
because of lower radiation treatment doses.24 Excess risk for breast
cancer was also shown after total-body irradiation at a young age.12
GI tract SMNs occur in excess many years after childhood
cancer (SIRs range from 2.0 to 30.0).10,27-29 The CCSS reported
that survivors treated with abdominal radiation experienced an
11-fold increased risk for GI SMNs (SIR, 11.2; 95% CI, 7.6 to
16.4).27 The St Jude Lifetime Cohort (SJLIFE) showed a radiation
dose-response by 10-Gy increments of prescribed dose for colon
cancer,28 whereas a relative risk per dose (Gy) to digestive organs of
1.13 was reported in Europe.29 The BCCSS investigators reported
a nearly ﬁvefold increased risk for GI cancers (SIR, 4.6; 95% CI, 3.8
to 5.6). Cumulative incidence of colorectal cancer by age 50 years was
1.4% (95% CI, 0.7% to 2.6%) for survivors treated with abdomi-
nopelvic irradiation, similar to rates observed in individuals with two
or more ﬁrst-degree relatives affected by colorectal cancer.10
A summary of six studies of subsequent sarcomas among
survivors of childhood cancer30 showed a linear dose-response. 10
Gy, with a possible decrease at doses. 40 Gy for bone sarcoma, and
with higher relative risks for bone sarcoma compared with STS.
Nonmelanoma skin cancer, most often basal cell carcinoma, rep-
resents the most common subtype of solid cancer after radiotherapy,
of which . 90% occur in the radiation ﬁeld (EOR per Gy, 1.09).31
Most studies examining radiotherapy-associated SMNs ana-
lyze radiotherapy from the era of two-dimensional imaging.
However, dose distribution across healthy tissues is changed with
modern radiotherapy techniques, such as intensity-modulated
radiotherapy and proton therapy. Proton beam radiotherapy in-
volves no dose deposition in tissues behind the tumor, which could
reduce SMN risk, but because of small sample size and other
methodologic challenges, the single study on SMN risk after
proton therapy is inconclusive.32 It will be critical to study how
these changes in technique have effected SMN risk among sur-
vivors treated more recently.
Chemotherapy and SMN Development
The best-established association between chemotherapy and
SMNs is for therapy-related acute myeloid leukemia (t-AML) and
therapy-related myelodysplastic syndrome (t-MDS). Dose-
dependent risks for t-AML and t-MDS are high (. 10-fold in-
creased) after almost all alkylating agents, as well as topoisomerase
II inhibitors33-36; however, the leukemogenicity of different agents
varies substantially and the AER is low because of the low back-
ground risk. t-AML after alkylating-agent exposure typically arises
after a latency of 5 to 8 years, is frequently preceded by MDS, and
often has a complex karyotype with chromosome 5 and 7 ab-
normalities.33 In contrast, t-AML after topoisomerase II inhibitor
exposure typically arises , 3 years after therapy, is rarely pre-
ceded by MDS, and is most frequently characterized by 11q23
rearrangements.37
Chemotherapy also increases risk for nonhematologic SMNs,
which typically occur. 10 years after exposure.33 Alkylating-agent
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Fig 2. Fitted radiation dose response by type of second cancer, on the basis of
previously published reports from the Childhood Cancer Survivor Study. Reprinted
with permission.15
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exposure increases risk for GI, thyroid, lung, breast, and blad-
der cancers, as well as sarcoma.22,23,28,38-43 Speciﬁcally, cyclo-
phosphamide increases sarcoma risk in a dose-dependent
manner.12,38,42,44 Furthermore, cyclophosphamide equivalent
doses of . 18,000 mg/m2 increase breast cancer risk by threefold
(SIR, 3.0; 95% CI, 1.2 to 7.7),41 and procarbazine and platinum
have been associated with 3.2-fold (95%CI, 1.1 to 9.4) and 7.6-fold
(95% CI, 2.3 to 25.5) increased risks, respectively, for GI SMNs.40
Procarbazine-related risks for the GI tract may be related to direct
exposure with the mucosa,28,39,44 whereas the mechanisms of
carcinogenesis for agents administered intravenously and for other
malignancies are unknown.
Risk for breast cancer and other solid malignancies, including
sarcoma, are increased after anthracycline exposure.12,41,44 In the
CCSS cohort, risk for breast cancer in survivors treated with
. 250 mg/m2 anthracycline and without a history of chest ra-
diotherapy is increased by nearly fourfold compared with risk in the
general population (SIR, 3.8; 95%CI, 1.7 to 8.3).41 TheDCOG-LATER
cohort reported similar ﬁndings, with a dose-dependent relationship
between breast cancer risk and doxorubicin (Ptrend , .001).
12 In the
CCSS and DCOG-LATER reports, breast cancer risk was highest after
Li-Fraumeni syndrome–associated cancers, suggesting a possible in-
teraction between chemotherapy and genetic predisposition.12,41
Chemotherapy can also indirectly affect SMN risk. In studies
of adolescent and young adult survivors of HL,22,45,46 higher
cumulative procarbazine exposure was associated with a greater
reduction of breast cancer risk, with 30% and 67% risk reduc-
tions for regimens of , 8.4 g/m2 and . 8.4 g/m2 procarbazine,
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respectively.45,46 This risk reduction seems to be due to the higher
frequency of premature menopause in patients treated more in-
tensively with chemotherapy and their resultant reduced exposure
to ovarian hormones.46-48 Similarly, high cumulative alkylator
exposure signiﬁcantly reduced breast cancer risk in the CCSS
cohort,26 in contrast to earlier CCSS results that did not show
a reduced breast cancer risk after alkylator therapy.49 Breast cancer
risk also increases in women with . 10 years of ovarian function
after chest radiotherapy compared with those with less.26,46,48
Genetics and SMN Development
Genomic advances in the last decade have expanded our
understanding of cancer predisposition. Broadly, genetic contri-
butions to cancer range from rare, highly penetrant variants that
are often associated with familial cancer susceptibility syndromes
to more common genetic variants associated with weakly or
modestly elevated risk for cancer in the general population.
Multiple primary cancers within an individual can occur in
several cancer susceptibility syndromes50; diagnoses often include
rare histologies or occurrence at younger than expected ages. Most
variants confer risk through an autosomal dominant inheritance
pattern, although a few exhibit autosomal recessive, X-linked, or
Y-linked patterns. Examples of inherited cancer predisposition
syndromes are listed in Table 1. Understanding of the penetrance of
and risks associated with these mutations, particularly in the
absence of established family history, is evolving rapidly with the
expansion of gene panel testing in recent years.
Research is increasingly focused on whether germline genetic
variation modiﬁes risk for treatment-related SMNs. Sensitivity to
damage from ionizing radiation exposure has been reported
among individuals with several cancer predisposition syndromes,
such as ataxia telangiectasia, and in experimental studies dem-
onstrating cellular radiosensitivity.52,53 In the general population,
most studies have focused on genetic variation in DNA damage
detection and repair mechanisms as potential modiﬁers of
treatment-related SMN risks, as reviewed recently.54 However,
these studies are limited by small sample sizes, insufﬁcient
treatment exposure data, or lack of replication of the reported
ﬁndings. More recently, studies have agnostically interrogated
common genetic variation across the genome to identify vari-
ants associated with SMN risk, including studies of t-MDS and
t-AML,55 SMNs after HL,56 and breast cancer after childhood
cancer.57 Expansion of these studies through large-scale genomics
efforts in survivors of cancer, such as the CCSS and the SJLIFE
Cohort, should provide important insights into the role of genetic
susceptibility in multiple primary cancers.
SURVEILLANCE AND INTERVENTION
In 2003, the Institute of Medicine called for lifelong risk-based
health care for survivors of childhood cancer.58 Given the high risk
for morbidity and mortality resulting from SMNs, the Children’s
Oncology Group (COG) and others developed consensus-based
surveillance guidelines for SMNs,59,60 with the goal of detecting
SMNs at earlier, more treatable stages. Guideline groups worldwide
have formed the International Guideline Harmonization Group
(IGHG) to provide harmonized evidence-based guidelines.61
Examination of other populations at increased cancer risk
have shown that, for some solid cancers, early initiation of sur-
veillance may improve outcomes. Breast cancer surveillance
guidelines60,62-64 have been prioritized, given the increased risk
among survivors exposed to chest irradiation. Mammogram
screening in high-risk survivors is associated with earlier breast
cancer detection,65 and combination breast magnetic resonance
imaging and mammogram screening in survivors exposed to chest
radiotherapy before age 30 years increases the speciﬁcity and
detection of invasive breast cancer and ductal carcinoma in situ,
a ﬁnding that is now reﬂected in screening guidelines.60,62-64,66 The
COG, DCOG-LATER, and the IGHG guidelines recommend that
screening begin at age 25 years or 8 years after treatment, whichever
occurs later. Recently, the COG has decreased the radiation ex-
posure threshold to 10 Gy for initiating screening, consistent with
the 2010 Dutch recommendations.60,62 The COG, unlike other
guidelines, recommends annual colonoscopy in survivors exposed
to abdominal or pelvic radiation therapy, beginning at age 35 or 10
years after radiation exposure, whichever occurs last.60 IGHG
recommendations for colorectal cancer surveillance are expected in
2018. For skin cancer screening, the COG recommends yearly
dermatologic examinations of the radiation ﬁeld.62
Routine screening for thyroid cancer and CNS neoplasms
remains controversial. Studies examining annual thyroid ultra-
sound surveillance suggest that a yearly physical examination is
sufﬁcient and may minimize the harm associated with over-
diagnosis and overtreatment.67 For survivors exposed to neck
radiation, the COG recommends ultrasound and ﬁne needle as-
piration for palpable nodules. Similarly, routine radiographic
screening for meningiomas is currently not recommended.62
Screening programs are recommended for survivors with
known germline cancer predisposition syndromes, such as Li-
Fraumeni syndrome, Lynch syndrome, and familial retinoblas-
toma. According to one study, nearly 10% of survivors of childhood
cancer may harbor an actionable germline genetic mutation68; thus,
it is imperative that risk-based care include yearly review of family
history and referral for genetic counseling for survivors with a history
suggestive of a cancer predisposition syndrome.
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Table 1. Examples of Surveillance for Potential SMN in Patients with Identiﬁed Cancer Predisposition Syndromes
Cancer Predisposition Syndrome
(associated gene) Potential SMN Surveillance/Prevention Guidelines
Li-Fraumeni syndrome (TP53) CNS tumors Annual brain*
Sarcomas Total body MRI*
Leukemia Annual mammogram and breast MRI surveillance starting at
age 20-25 years, or individualized on the basis of earliest
age of onset in family*
Breast cancer Consider bilateral prophylactic mastectomy*
Colorectal cancer Biennial colonoscopies beginning at age 40 years, or 10 years
before the earliest known colon cancer in the family*
Upper gastrointestinal tumors (eg, stomach and
esophagus)
Annual dermatology examination*
Lung cancer Annual abdominal ultrasound*
Melanoma
Pancreatic cancer
Adrenocortical cancer
Kidney cancer
Gonadal germ cell tumors
Hereditary breast or ovarian cancer
(BRCA 1/2)
Breast cancer (in men and women) Annual screening mammogram to begin 10 years before the
age of diagnosis of the youngest family member but not
, 30 years old
Ovarian cancer Annual screening breast MRI to begin 10 years before the
youngest family member but not , 25 years old†
Fallopian tube cancer Consider risk reduction strategies (eg, prophylactic
mastectomy and/or oophorectomy, tamoxifen)†
Pancreatic cancer
Prostate cancer
Colorectal cancer/polyposis
syndromes
FAP FAP: Annual ﬂexible sigmoidoscopy or colonoscopy between
ages 10 and 15 years until surgery is warranted.† After
colectomy, upper endoscopy is recommended starting at
ages 20 to 25 years.
Colorectal cancer Lynch syndrome: Colonoscopy every 2 years beginning at
age 20 to 25 years until age 40 years, then annually
thereafter‡
Stomach cancer
Small bowel malignancy
Pancreatic cancer
Biliary tree
Papillary thyroid cancer
Medulloblastoma (if not primary childhood cancer)
Hepatoblastoma (if not primary childhood cancer)
Lynch syndrome
Colorectal cancer
Pancreatic cancer
Endometrial cancer
Breast cancer
Ovarian cancer
Stomach cancer
Small bowel malignancy
Prostate cancer
Liver cancer
Urinary tract cancer
Kidney cancer
Bile duct cancers
Familial retinoblastoma (RB1) Osteosarcoma Consider annual MRI in previous radiation ﬁeld
Soft tissue sarcoma Annual physical examination
Melanoma Annual dermatology examination (with particular attention to
the previous radiation ﬁeld)§
Lung cancer
Lymphoma
Bladder cancer
Endometrial cancer
Breast cancer
Brain tumors
Cancers of the nasopharynx
Abbreviations: FAP, familial adenomatous polyposis; MRI, magnetic resonance imaging; SMN, subsequent malignant neoplasm.
*Modiﬁed Toronto Protocol.51
†National Comprehensive Cancer Network guidelines.
‡American College of Gastroenterology guidelines.
§Children’s Oncology Group long-term follow-up guidelines.
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Despite surveillance recommendations, many primary care
providers are unaware of,69 and many survivors are often non-
adherent with,70,71 recommended screenings. Interventions have
been developed to improve awareness and adherence to screening
guidelines for breast and skin cancer.72,73 Additional study is
necessary to inform SMN surveillance recommendations and to
improve adherence as well as survivor and provider knowledge of
these recommendations.
Few primary prevention strategies are available for SMN
reduction. A phase II, multicenter, randomized, placebo-
controlled trial is currently evaluating the use of low-dose ta-
moxifen for 2 years in female patients who received $ 12 Gy of
chest irradiation before age 40 years. Prophylactic mastectomy is
also offered to women exposed to chest radiotherapy at a young
age.
In conclusion, we have learned a great deal about SMN risk,
risk factors, genetic predisposition, and surveillance. New therapies
in clinical practice necessitate ongoing research on SMN risk;
prioritization of surveillance efforts and survivor and provider
education are also necessary. Improved survival and recognition of
late effects, including SMNs, reinforce the need for ongoing
upfront therapy modiﬁcations to moderate late health risks and to
improve long-term survivor health.
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